Informationsseite des RKI rund um Impfen und COVID-19
Leitfaden für Ärzt:innen im Patient:innen- und Bürger:innengespräch
Informationen rund um die Corona-Schutzimpfung
Diese Informationen sind zur Weitergabe an Patient:innen und Bürger:innen.
Unsere Infoboxen zeigen das Ansteckungs-, Erkrankungs- und Sterberisiko für Menschen verschiedenen Alters, wenn sie in Kontakt mit dem Influenza- oder Corona-Virus kommen (z.B. durch engen Kontakt mit einem infizierten Haushaltsmitglied) und die Risiken eines engen Kontaktes für Menschen verschied...enen Alters, wenn man selbst mit dem Influenza- oder Corona-Virus infiziert ist.
Zu jeder Infobox finden Sie im Begleittext Hintergrundinformationen zur Erstellung und zu den dahinter liegenden Daten.
more
The European Medicines Agency (EMA) is evaluating potential COVID-19 treatments and vaccines to enable promising medicines to reach patients as soon as possible. It is also interacting with medicine developers and making use of real-world data to monitor the safety and effectiveness of medicines use...d in patients with COVID-19.
more
Vertreter besorgniserregender Virusvarianten (variants of concern, kurz VOC) wurden weltweit aber auch in Europa, identifiziert. Molekularbiologische Details zu den Varianten sind unter SARS-CoV-2: Virologische Basisdaten und Virusvarianten abrufbar.
Die Bundesländer sind für die Organisation der Impfung gegen Corona zuständig. Sie betreiben die Impfzentren, vergeben Termine und planen den Einsatz der mobilen Teams in Pflegeheimen. Hier finden Sie die Infoseite Ihres Bundeslandes zur Corona-Schutzimpfung.
Ausführliche Informationen zu klinischen Prüfungen und Risiken für bestimmte Gruppe sowie zu Wechselwirkungen und Nebenwirkungen.
Ausführliche Informationen zu klinischen Prüfungen und Risiken für bestimmte Gruppen sowie zu Wechselwirkungen und Nebenwirkungen von Impfstoffen und Arzneimitteln zu COVID-19 und SARS-CoV-2
This website has been created to provide accurate and up-to-date information about Sputnik V.
COVAXINTM, India's indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) h...igh containment facility.
The vaccine received DCGI approval for Phase I & II Human Clinical Trials and the trials commenced across India from July, 2020.
After successful completion of the interim analysis from the Phase 1 & 2 clinical trials of COVAXINTM, Bharat Biotech received DCGI approval for Phase 3 clinical trials in 26,000 participants in over 25 centres across India.
more
Navegue pelos dados do Sistema Único de Saúde - SUS, com informações estratégicas e conheça tudo sobre a COVID-19 de forma transparente e analítica
January 2021. Save the Children urges governments and donors to take five urgent steps to ensure that children who were in school prior to COVID-19 closures can safely return:
Financial support for the world’s poorest families, so they can send their children to school and keep them healthy;
...
Catch-up classes for students who re-enter the formal education system;
Water, sanitation and hygiene facilities in schools, to make them COVID-19 safe for students, teachers and their families;
National back to school communications campaigns to inform communities that it is safe for children to return;
Effective training for teachers to keep everyone safe during the COVID-19 pandemic.
more
Material in multiple languages
CANVax is the first online database of its kind in Canada to support immunization program planning and promotional activities to improve vaccine acceptance and uptake in Canada. CANVax houses a collection of curated evidence based products and resources to make it eas...ier for public health professionals to access and gather resources to inform activities aimed at improving vaccine coverage.
more
COVID-19 Vaccine Introduction Readiness Assessment Tool (VIRAT2), developed by WHO-PAHO, UNICEF, World Bank, Gavi, and other partners is a tool to help prepare countries for the introduction a COVID-19 vaccine.
It provides a roadmap for introduction and a structured framework for countries to self-...monitor their readiness progress against key milestones. It includes an excel template for Ministries of Health to complete with support from partners and PAHO Country Offices.
The VIRAT dashboard helps countries highlight the critical activities and technical areas that should be initiated, continued, or strengthened. Also, it allows PAHO and partners to identify areas where support may be needed and identify alternative forms to mobilize resources.
more
18 Janaury 2021
EU/EEA Member States and the UK have increased their laboratory capacity tremendously over the past 11 months as the majority of the Member States reported sufficient testing capacity until March 2021.
Many countries are adding rapid antigen detection tests (RADT) to their ...testing strategies in order to reduce pressure on RT-PCR testing.
Some Member States have already included RADT in their case definition.
The main bottlenecks, such as shortages of laboratory consumables and human resources, as well as sample storing facilities, continue to exist and may affect the overall laboratory response to COVID-19.
more
ASLM in collaboration with the Africa Centres for Disease Control and Prevention, and in partnership with the Clinton Health Access Initiative, Amref and Last Mile Health present the Quality Assurance Framework for SARS-CoV-2 Antigen Rapid Testing for Diagnosis of COVID-19. This framework aims to pr...ovide general technical guidance to African Union Members States on the rollout, establishment, implementation, monitoring, and evaluation of SARS-CoV-2 Ag RDT interventions so as to effectively and efficiently detect, control and minimise errors in the performance of COVID-19 laboratory testing processes. It describes the core components for quality assurance, resources mobilisation and advocacy for scale up, monitoring, evaluation, learning and accountability for SARS-CoV-2 implementation.
more